Sami Belhadj

11PUBLICATIONS
75CO-AUTHORS
Molecular targetsMedical biotechnology diagnostics (incl. biosensors)Liquid biopsiesPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 25, 2026
SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers.

|Mar 19, 2026
Sequencing approaches in hereditary cancer testing: strengths, limitations and future directions.

Sami Belhadj, Christopher J Hatch, Holly LaDuca

|Nov 08, 2022
NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects.

Sami Belhadj, Aliya Khurram, Chaitanya Bandlamudi

|Aug 09, 2022
Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities.

Kenneth Offit, Catherine M Sharkey, Dina Green

|Apr 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.

Semanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann

|Nov 23, 2021
Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations.

Ying L Liu, Karen A Cadoo, Semanti Mukherjee

Pageof 2

Frequent Collaborators

4 joint publications

Mariona Terradas

4 joint publications

Laura Valle

4 joint publications

Gabriel Capellá

4 joint publications

Michael Walsh